ReviewJournal of pharmaceutical policy and practice2026
Asthma and chronic obstructive disease overlap (ACO), a systematic review of prevalence and co-morbidity factors based on diagnostic criteria.
Review in Journal of pharmaceutical policy and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Asthma and chronic obstructive pulmonary disease (COPD) overlap (ACO) is a complex pathological condition involving features of both asthma and COPD. While the individual diagnoses of asthma and COPD are well defined, there is no consensus on the definition or diagnostic criteria for ACO. This lack of standardisation contributes to inconsistencies in data interpretation and reported prevalence. In this study, we aimed to systematically review the differences in diagnostic criteria and prevalence of ACO across studies, to identify the co-morbidities, and provide insights into the clinical factors associated with ACO. Methods: A systematic review was conducted in accordance with the PRISMA guidelines. A total of 1,033 articles were identified from three electronic databases, of which 37 studies met the inclusion criteria and were included in the final analysis. Results: The reported prevalence of ACO varied widely depending on the study population and diagnostic criteria used. ACO prevalence ranged from 0.55% to 12.9% in the general population, 11.8% to 53.3% among asthma cohorts, 10.5% to 56.2% among COPD cohorts, 4.3% to 47.8% among combined asthma and COPD cohorts, and 3.2% to 18.4% among other respiratory or chronic airway disease cohorts. ACO was commonly associated with co-morbidities such as cardiovascular disease, gastroesophageal reflux disease, diabetes, and allergic rhinitis. Clinical factors linked to ACO included higher body mass index, smoking history, and reduced lung function (FEV1%). Conclusion: The wide variability in ACO prevalence reflects differences in diagnostic definitions and study populations. Patients with ACO experience increased morbidity, including higher rates of exacerbations, hospitalisations, and poorer quality of life, likely due to the presence of multiple co-morbidities. Standardised diagnostic criteria are essential to improve disease recognition and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.